A KDOQI expert work group reviewed and commented on the 2025 AHA/ACC Guideline for hypertension management, focusing on implications for adults with non-dialysis-dependent CKD (stages 1–5), including areas where the guideline does not offer formal recommendations (e.g., medication interactions, electrolyte imbalances, kidney injury).
The KDOQI work group broadly supports the 2025 AHA/ACC recommendations, including the <130/80 mm Hg blood pressure target and the adoption of the PREVENT calculator (which integrates cardiovascular, kidney, and metabolic parameters), while identifying gaps and additional considerations specific to CKD management.
This is an expert commentary rather than an original study, so conclusions reflect consensus opinion rather than new primary evidence. The commentary explicitly excludes patients on maintenance dialysis, limiting applicability to that population.
Clinicians managing CKD patients should apply the <130/80 mm Hg blood pressure target and use the PREVENT risk calculator, which now incorporates kidney health parameters. Pay special attention to CKD-specific concerns such as medication interactions, electrolyte imbalances, and acute kidney injury risk not fully addressed in the AHA/ACC guideline itself.